Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy

International Journal of Urology

Volumn 16, Issue 3, 2009, Pages 337-338

  Takeshita, Hideki ^a   Kawakami, Satoru ^a   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; BLADDER TUMOR; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HORMONAL THERAPY; HUMAN; LETTER; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; WITHDRAWAL SYNDROME;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; BIOPSY, NEEDLE; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; SALVAGE THERAPY; SUBSTANCE WITHDRAWAL SYNDROME; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 62149107819     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02189.x     Document Type: Letter

References (4)

1. Paul R, Breul J. Antiandrogen withdrawal syndrome associated with prostate cancer therapies. Drug Saf. 2000 23 : 381 90.
2. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 1993 150 : 908 13.
3. Noguchi K, Teranishi J, Uemura H, Fujikawa N, Saito K, Murai T. Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports. Int. J. Urol. 2006 13 : 1259 61.
4. Kundranda MN, Muslimani A, Daw HA, Spiro TP. Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal. Clin. Genitourin. Cancer 2007 5 : 401 2.